T. Z. Khan, J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso et al., Early pulmonary inflammation in infants with cystic fibrosis, Am J Respir Crit Care Med, vol.151, pp.1075-82, 1995.

M. S. Muhlebach, P. W. Stewart, M. W. Leigh, and T. L. Noah, Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients, Am J Respir Crit Care Med, vol.160, pp.186-91, 1999.

C. Verhaeghe, K. Delbecque, L. De-leval, C. Oury, and V. Bours, Early inflammation in the airways of a cystic fibrosis foetus, J Cyst Fibros, vol.6, pp.304-312, 2007.

M. Roulet, P. Frascarolo, I. Rappaz, and M. Pilet, Essential fatty acid deficiency in well nourished young cystic fibrosis patients, Eur J Pediatr, vol.156, pp.952-958, 1997.

L. Aldámiz-echevarría, J. A. Prieto, F. Andrade, J. Elorz, A. Sojo et al., Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy, Pediatr Res, vol.66, pp.585-594, 2009.

M. Wouthuyzen-bakker, F. A. Bodewes, and H. J. Verkade, Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice, J Cyst Fibros, vol.10, pp.150-158, 2011.

M. Sinaasappel, M. Stern, J. Littlewood, S. Wolfe, G. Steinkamp et al., Nutrition in patients with cystic fibrosis: a European Consensus, J Cyst Fibros, vol.1, pp.51-75, 2002.

A. M. Giudetti and R. Cagnazzo, Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases, Prostaglandins Other Lipid Mediat, vol.99, pp.57-67, 2012.

C. Oliver and H. Watson, Omega-3 fatty acids for cystic fibrosis, Cochrane Database Syst Rev, vol.11, p.2201, 2013.

M. Mimoun, T. C. Coste, J. Lebacq, P. Lebecque, P. Wallemacq et al., Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid, J Nutr, vol.139, pp.2358-64, 2009.

H. Tiesset, H. Bernard, N. Bartke, C. Beermann, E. Flachaire et al., n-3) longchain PUFA differentially affect resistance to Pseudomonas aeruginosa infection of male and female cftr-/-mice, J Nutr, vol.141, pp.1101-1108, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02178838

H. Tiesset, M. Pierre, J. Desseyn, B. Guery, C. Beermann et al., Dietary (n-3) polyunsaturated fatty acids affect the kinetics of pro-and antiinflammatory responses in mice with Pseudomonas aeruginosa lung infection, J Nutr, vol.139, pp.82-91, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02178624

J. H. Van_doorninck, P. J. French, E. Verbeek, R. H. Peters, H. Morreau et al., A mouse model for the cystic fibrosis delta F508 mutation, EMBO J, vol.14, pp.4403-4414, 1995.

D. Tetaert, M. Pierre, D. Demeyer, M. Husson, C. Galabert et al., Dietary n-3 fatty acids have suppressive effects on mucin upregulation in mice infected with Pseudomonas aeruginosa, Respir Res, vol.11, pp.1-11, 2007.
URL : https://hal.archives-ouvertes.fr/hal-02178627

J. Bilsborough, E. Chadwick, S. Mudri, X. Ye, W. R. Henderson et al., TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma, Clin Exp Allergy, vol.38, pp.1959-68, 2008.

A. J. Viera and J. M. Garrett, Understanding interobserver agreement: the kappa statistic, Fam Med, vol.37, pp.360-363, 2005.

M. Husson, D. Ley, C. Portal, M. Gottrand, T. Hueso et al., Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids, J Infect, vol.73, pp.523-558, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02178827

J. N. Snouwaert, K. K. Brigman, A. M. Latour, N. N. Malouf, R. C. Boucher et al., An animal model for cystic fibrosis made by gene targeting, Science, vol.257, pp.1083-1091, 1992.

B. G. Zeiher, E. Eichwald, J. Zabner, J. J. Smith, A. P. Puga et al., A mouse model for the delta F508 allele of cystic fibrosis, J Clin Invest, vol.96, pp.2051-64, 1995.

P. J. Byard, Early childhood growth in patients with cystic fibrosis, Ann Hum Biol, vol.17, pp.483-99, 1990.

M. W. Konstan, S. M. Butler, M. Wohl, M. Stoddard, R. Matousek et al., Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis, J Pediatr, vol.142, pp.624-654, 2003.

B. S. Zemel, A. F. Jawad, S. Fitzsimmons, and V. A. Stallings, Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: Analysis of the Cystic Fibrosis Foundation National CF Patient Registry, J Pediatr, vol.137, pp.374-80, 2000.

L. A. Rosenberg, M. D. Schluchter, A. F. Parlow, and M. L. Drumm, Mouse as a model of growth retardation in cystic fibrosis, Pediatr Res, vol.59, pp.191-196, 2006.

B. Lubamba, F. Huaux, J. Lebacq, E. Marbaix, B. Dhooghe et al., Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice, J Cyst Fibros, vol.11, pp.266-73, 2012.

R. Legssyer, F. Huaux, J. Lebacq, M. Delos, E. Marbaix et al., Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice, Respir Res, vol.7, p.134, 2006.

B. Dhooghe, S. Noël, F. Huaux, and T. Leal, Lung inflammation in cystic fibrosis: pathogenesis and novel therapies, Clin Biochem, vol.47, pp.539-585, 2014.

T. L. Noah, H. R. Black, P. W. Cheng, R. E. Wood, and M. W. Leigh, Nasal and bronchoalveolar lavage fluid cytokines, J Infect Dis, vol.175, pp.638-685, 1997.

S. D. Freedman, D. Weinstein, P. G. Blanco, P. Martinez-clark, S. Urman et al., Characterization of LPS-induced lung inflammation in cftr-/-mice and the effect of docosahexaenoic acid, J Appl Physiol, vol.92, pp.2169-76, 2002.

G. Bergamini, C. Cigana, C. Sorio, D. Peruta, M. Pompella et al., Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells, Am J Respir Cell Mol Biol.spirCell MolBiol, vol.41, pp.199-206, 2009.

S. Tirkos, S. Newbigging, V. Nguyen, M. Keet, C. Ackerley et al., Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator, Respir Res, vol.7, p.51, 2006.

M. Wilke, R. M. Buijs-offerman, J. Aarbiou, W. H. Colledge, D. N. Sheppard et al., Mouse models of cystic fibrosis: phenotypic analysis and research applications, European Cystic Fibrosis Society, vol.10, pp.152-71, 2011.

E. M. Bruscia, P. X. Zhang, C. Barone, B. J. Scholte, R. J. Homer et al., Increased susceptibility of cftr-/-mice to LPS-induced lung remodeling, vol.310, pp.711-720, 2016.

H. Wu, J. Yang, E. M. Su, L. Li, C. Zhao et al., Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice, PLoS One, vol.9, p.93003, 2014.

J. Palomo, T. Marchiol, J. Piotet, L. Fauconnier, M. Robinet et al., Role of IL-1?? in experimental cystic fibrosis upon P. aeruginosa Infection, PLoS One, vol.9, pp.1-17, 2014.

A. Van-heeckeren, R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis et al., Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa, J Clin Invest, vol.100, pp.2810-2815, 1997.

S. D. Freedman, M. H. Katz, E. M. Parker, M. Laposata, M. Y. Urman et al., A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice, Proc Natl Acad Sci U S A, vol.96, pp.13995-4000, 1999.

S. D. Freedman, P. G. Blanco, M. M. Zaman, J. C. Shea, M. Ollero et al., Association of cystic fibrosis with abnormalities in fatty acid metabolism, N Engl J Med, vol.350, pp.560-569, 2004.

M. Meyer, F. Huaux, X. Gavilanes, S. Van-den-brûle, P. Lebecque et al., Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis, Am J Respir Cell Mol Biol, vol.41, pp.590-602, 2009.

C. Delayre-orthez, J. Becker, I. Guenon, V. Lagente, J. Auwerx et al., PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse, Respir Res, vol.6, p.91, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00090225

M. Hecker, A. Behnk, R. E. Morty, N. Sommer, I. Vadász et al., PPAR-? activation reduced LPS-induced inflammation in alveolar epithelial cells, Exp Lung Res, vol.41, pp.393-403, 2015.

V. Reynders, S. Loitsch, C. Steinhauer, T. Wagner, D. Steinhilber et al., Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes, Respir Res, vol.7, p.104, 2006.

M. R. Al-turkmani, S. D. Freedman, and M. Laposata, Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis, Prostaglandins Leukot Essent Fat Acids, vol.77, pp.309-327, 2007.

B. Strandvik, E. Gronowitz, F. Enlund, T. Martinsson, and J. Wahlström, Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis, J Pediatr, vol.139, pp.650-655, 2001.